IL-17/IL-17A Antibody [PE] - (Research Grade ixekizumab Biosimilar)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28729PE
Recombinant Monoclonal Antibody

Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
PE (Excitation = 488 nm, Emission = 575 nm)
Antibody Source
Recombinant Monoclonal Human IgG4
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
CTLA-8 / IL-17a
Reactivity Notes
Predicted species reactivity: Cynomolgus
Clonality
Monoclonal
Host
Human
Isotype
IgG4
Applications for IL-17/IL-17A Antibody [PE] - (Research Grade ixekizumab Biosimilar)
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-17/IL-17A
Long Name
Interleukin 17
Alternate Names
CTLA-8, CTLA8, IL-17A, IL17, IL17A
Gene Symbol
IL17A
Additional IL-17/IL-17A Products
Product Documents for IL-17/IL-17A Antibody [PE] - (Research Grade ixekizumab Biosimilar)
Product Specific Notices for IL-17/IL-17A Antibody [PE] - (Research Grade ixekizumab Biosimilar)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...